Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: explora...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter K. Nishikawa
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors K. Nishikawa1, K. Fujitani2, H. Inagaki3, Y. Akamaru4, S. Tokunaga5, M. Takagi6, S. Tamura7, N. Sugimoto8, T. Shigematsu9, T. Yoshikawa10, T. Ishiguro11, M. Nakamura12, T. Yamane13, M. Yamada14, M. Imano15, S. Iijima16, A. Nashimoto17, S. Morita18, Y. Miyashita19, A. Tsuburaya20, J. Sakamoto21, T. Tsujinaka22
  • 1Osaka National Hospital, Osaka, Japan, /
  • 2Department of Surgery, Osaka Prefectural General Medical Center, Osaka, Japan, /
  • 3Gifu Central Hospital, Gifu, Japan, /
  • 4Osaka Kose-Nenkin Hospital, Osaka, Japan, /
  • 5Osaka City General Hospital, Osaka, Japan, /
  • 6Shizuoka General Hospital, Shizuoka, Japan, /
  • 7Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan, /
  • 8Osaka Medical Center for Cancer and Cardiovascular Disease, Medical Oncology, Osaka, Japan, /
  • 9Saiseikai Shiga Prefectural Hospital, Ritto, Japan, /
  • 10Kanagawa Cancer Center, Yokohama, Japan, /
  • 11Saitama Medical Center, Kawagoe, Japan, /
  • 12Aizawa Hospital, Matsumoto, Japan, /
  • 13Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan, /
  • 14Gifu Municipal Hospital, Gifu, Japan, /
  • 15Kinki University, Osakasayama, Japan, /
  • 16Department of Surgery, Kinki Central Hospital, Itami, Japan, /
  • 17Niigata Cancer Center Hospital, Niigata, Japan, /
  • 18Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, /
  • 19Date Center, Epidemiological & Clinical Research Information Network, Kyoto, Japan, /
  • 20Yokohama City University Medical Center, Yokohama, Japan, /
  • 21Tokai Central Hospital, Kakamigahara, Japan, /
  • 22Kaizuka City Hospital, Dept of Gastroenterology, Osaka, Japan, /

Abstract

Second-line chemotherapy (SLC) was reported to improve the survival of advanced gastric cancer (AGC). A randomized phase III study of second-line irinotecan plus cisplatin versus irinotecan alone in patients with AGC refractory to S-1 monotherapy, the TRICS trial, revealed that both irinotecan based chemotherapies were effective with favorable long-term survivals and generally well tolerated. Eligible patients included patients with recurrence within 6 months after the completion of adjuvant therapy with S-1 (early relapse cases), or patients with tumor progression after first-line S-1 for an advanced cancer (progressive cases), in the TRICS trial. However, it is unclear whether the efficacy and safety in early relapse cases were different from these in progressive cases or not.